Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer
Nitroglycerin decreases hypoxia-induced resistance to antitumor drugs due to inhibition of
Hypoxia Inducible Factor alfa (HIF-1α), it increases oxygen pressure in tumoral tissue by
augmenting tumor blood flow, increases apoptosis, activation of p53, and induces cellular
growth inhibition. Randomized studies showed that the addition of transdermal nitroglycerin
to non small cell lung cancer (NSCLC) patients with metastasis treated with vinorelbine and
cisplatin achieved a significantly better global response to treatment than conventional
treatment
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to progression, over-all survival
5 years
No
Oscar A Rodriguez, MD
Principal Investigator
National Counsil of Science and Technology
Mexico: National Council of Science and Technology
CB332/08
NCT00886405
July 2006
January 2010
Name | Location |
---|